Effect of the myeloperoxidase inhibitor AZD3241 on microglia: A PET study in Parkinson's disease

Brain

Volumn 138, Issue 9, 2015, Pages 2687-2700

  Jucaite, Aurelija ^a,b   Svenningsson, Per ^b   Rinne, Juha O ^c   Cselényi, Zsolt ^a,b   Varnäs, Katarina ^b   Johnström, Peter ^a,b   Amini, Nahid ^b   Kirjavainen, Anna ^c   Helin, Semi ^c   Minkwitz, Margaret ^d   Kugler, Alan R ^d   Posener, Joel A ^d   Budd, Samantha ^d,e   Halldin, Christer ^b   Varrone, Andrea ^b   Farde, Lars ^a,b  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b KAROLINSKA INSTITUTE   (Sweden)

^c UNIVERSITY OF TURKU   (Finland)

^d ASTRAZENECA   (United Kingdom)

^e BIOGEN   (United States)

Author keywords

18kDa translocator protein; microglia; Parkinson's disease; positron emission tomography

Indexed keywords

1,2,3,5 TETRAHYDRO 1 (2 ISOPROPOXYETHYL) 2 THIOXOPYRROLO[3,2 D]PYRIMIDIN 4 ONE; CARRIER PROTEIN; DOPAMINE TRANSPORTER; MYELOPEROXIDASE; PLACEBO; RADIOPHARMACEUTICAL AGENT; REACTIVE OXYGEN METABOLITE; UNCLASSIFIED DRUG; [N ACETYL N (2 METHOXYBENZYL) 2 PHENOXY 5 PYRIDINAMINE] C 11; (METHYL-(11)C)N-ACETYL-N-(2-METHOXYBENZYL)-2-PHENOXY-5-PYRIDINAMINE; 4 AMINOBUTYRIC ACID RECEPTOR; ENZYME INHIBITOR; FLUORINE; PROTEIN BINDING; PYRIMIDINE DERIVATIVE; PYRIMIDINONE DERIVATIVE; PYRROLE DERIVATIVE; TSPO PROTEIN, HUMAN;

ADULT; AGED; ARTICLE; BLOOD SAMPLING; BRAIN REGION; CLINICAL ARTICLE; CLINICAL ASSESSMENT; CLINICAL EVALUATION; COMPARATIVE STUDY; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; EFFECT SIZE; ELECTROCARDIOGRAM; FATIGUE; FEMALE; GENETIC POLYMORPHISM; HUMAN; INSOMNIA; LABORATORY TEST; MALE; MICROGLIA; MULTICENTER STUDY; NAUSEA; NUCLEAR MAGNETIC RESONANCE SCANNER; OUTCOME ASSESSMENT; OXIDATIVE STRESS; PARKINSON DISEASE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; RISK ASSESSMENT; UNIFIED PARKINSON DISEASE RATING SCALE; VITAL SIGN; VOLUME OF DISTRIBUTION; BLOOD; CLINICAL TRIAL; DIAGNOSTIC USE; DOSE RESPONSE; DRUG EFFECTS; FOLLOW UP; GENETICS; MIDDLE AGED; PATHOLOGY; PHASE 2 CLINICAL TRIAL; SCINTISCANNING; SEVERITY OF ILLNESS INDEX; SINGLE NUCLEOTIDE POLYMORPHISM;

AGED; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; ENZYME INHIBITORS; FEMALE; FLUORINE RADIOISOTOPES; FOLLOW-UP STUDIES; HUMANS; MALE; MICROGLIA; MIDDLE AGED; PARKINSON DISEASE; POLYMORPHISM, SINGLE NUCLEOTIDE; POSITRON-EMISSION TOMOGRAPHY; PROTEIN BINDING; PYRIMIDINES; PYRIMIDINONES; PYRROLES; RECEPTORS, GABA; SEVERITY OF ILLNESS INDEX;

EID: 84940753656     PISSN: 00068950     EISSN: 14602156     Source Type: Journal    
DOI: 10.1093/brain/awv184     Document Type: Article

References (49)

1. Amini N, Nakao R, Schou M, Halldin C. Identification of PET radiometabolites by cytochrome P450, UHPLC/Q-ToF-MS and fast radio-LC: Applied to the PET radioligands [11C]flumazenil, [18F]FE-PE2I, and [11C]PBR28. Anal Bioanal Chem 2013; 405: 1303-10.
2. Bartels AL, Willemsen AT, Doorduin J, de Vries EF, Dierckx RA, Leenders KL. [11C]-PK11195 PET: Quantification of neuroinflammation and a monitor of anti-inflammatory treatment in Parkinson's disease? Parkinsonism Rel Disord 2010; 16: 57-9.
3. Bindslev N. Hill in hell. In: Drug-acceptor interactions. Co-Action Publishing; 2008. p. 257-82.
4. Briard E, Zoghbi SS, Imaizumi M, Gourley JP, Shetty HU, Hong J, et al. Synthesis and evaluation in monkey of two sensitive 11Clabeled aryloxyanilide ligands for imaging brain peripheral benzodiazepine receptors in vivo. J Med Chem 2008; 51: 17-30.
5. Brown EG, Wood L, Wood S. The medical dictionary for regulatory activities (MedDRA). Drug Safety 1999; 20: 109-17.
6. Catafau A, Tolosa E; DaTSCAN Clinically Uncertain Parkinsonian Syndromes Study Group. Impact of dopamine transporter SPECT using 123I-Ioflupane on diagnosis and management of patients with clinically uncertain Parkinsonian syndromes. Mov Disord 2004; 19: 1175-82.
7. Chauveau F, Boutin H, Van Camp N, Dollé F, Tavitian B. Nuclear imaging of neuroinflammation: A comprehensive review of [11C]PK11195 challengers. Eur J Nucl Med Mol Imaging 2008; 35: 2304-19.
8. Cselenyi Z, Olsson H, Halldin C, Gulyas B, Farde L. A comparison of recent parametric neuroreceptor mapping based on measurements with high affinity PET radioligands [11C]FLB457 and [11C]WAY 100635. Neuroimage 2006; 32: 1690-708.
9. Collste K, Cervenka S, Forsberg A, Varrone A, Amini N, Halldin C, et al. Test-retest reproducibility of [11C]PBR28 binding to TSPO in brain in control subjects. 10th International Symposium on Functional NeuroReceptor Mapping of the Living Brain, Amsterdam, 2014.
10. Darcourt J, Booij J, Tatsch K, Varrone A, Vander Borght T, Kapucu Ö, et al. EANM procedure guidelines for brain neurotransmission SPECT using 123I-labelled dopamine transporter ligands, version 2. Eur J Nucl Med Mol Imaging 2010; 37: 443-50.
11. Doble A, Malgouris C, Daniel M, Daniel N, Imbault F, Basbaum A, et al. Labelling of peripheral-type benzodiazepine binding sites in human brain with [3H]PK 11195: Anatomical and subcellular distribution. Brain Res Bull 1987; 18: 49-61.
12. Dodel R, Spottke A, Gerhard A, Reuss A, Reinecker S, Schimke N, et al. Minocycline 1-year therapy in multiple-system-atrophy: effect on clinical symptoms and [(11)C] (R)-PK11195 PET (MEMSA-trial). Mov Disord 2010; 25: 97-107.
13. Duke DC, Moran LB, Pearce RK, Graeber MB. The medial and lateral substantia nigra in Parkinson's disease: mRNA profiles associated with higher brain tissue vulnerability. Neurogenetics 2007; 8: 83-94.
14. Fahn S, Elton RL; Members of the UPARKINSON'S DISEASERS Development Committee. United Parkinson's disease rating scale. In: Fahn S, Marsden CD, Calne DB, Goldstein M, editors. Recent developments in Parkinson's disease. Florham Park, NJ: MacMillan Health Care Information; 1987. p. 153-64.
15. Farde L, Eriksson L, Blomquist G, Halldin C. Kinetic analysis of central [11C] raclopride binding to D2-dopamine receptors studied by PET: A comparison to the equilibrium analysis. J Cereb Blood Flow Metab 1989; 9: 696-708.
16. Fazio P, Svenningsson P, Forsberg A, Jönsson EG, Amini N, Nakao R, et al. Quantitative analysis of 18F-FE-PE2I binding to the dopamine transporter in Parkinson's disease. J Nucl Med 2015; 56: 714-20.
17. Folstein MF, Folstein SE, McHugh PR. "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. J Psych Res 1975; 12: 189-98.
18. Fujita M, Imaizumi M, Zoghbi SS, Fujimura Y, Farris AG, Suhara T, et al. Kinetic analysis in healthy humans of a novel positron emission tomography radioligand to image the peripheral benzodiazepine receptor, a potential biomarker for inflammation. Neuroimage 2008; 40: 43-52.
19. Galter D, Eriksson H, Olson L. Myeloperoxidase expression in postmortem human tissue and in animal models of Parkinson's disease. Neurosc Abstract/Poster 2007; 254. 1.
20. Gautier CA, Corti O, Brice A. Mitochondrial dysfunctions in Parkinson's disease. Rev Neurol (Paris) 2014; 170: 339-43.
21. Gerhard A, Pavese N, Hotton G, Turkheimer F, Meltem ES, Hammers A, et al. In vivo imaging of microglial activation with [11C](R)-PK11195 PET in idiopathic Parkinson's disease. Neurobiol Dis 2006; 21: 404-12.
22. Goetz CG, Fahn S, Martinez-Martin P, Poewe W, Sampaio C, Stebbins GT, et al. Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): Process, format, and clinimetric testing plan. Mov Disord 2007; 22: 41-7.
23. Goetz CG, Poewe W, Rascol O, Sampaio C, Stebbins GT, Counsell C, et al. Movement Disorder Society Task Force report on the Hoehn and Yahr staging scale: Status and recommendations. Mov Disord 2004; 19: 1020-8.
24. Gupta A, Dawson VL, Dawson TM. What causes cell death in Parkinson's disease? Ann Neurol 2008; 64 (Suppl 2): S3-15.
25. Guttman M, Stewart D, Hussey D, Wilson A, Houle S, Kish S. Influence of L-dopa and pramipexole on striatal dopamine transporter in early Parkinson's disease. Neurology 2001; 56: 1559-64.
26. Halldin C, Swahn CG, Farde L, Sedvall G. Radioligand disposition and metabolism. In: Comar D, editor. PET for drug development and evaluation. Dordrecht: Kluwer; 1995. p. 55-65.
27. Hoehn MM, Yahr MD. Parkinsonism: Onset, progression and mortality. Neurology 1967; 17: 427-42.
28. Hughes AJ, Daniel SE, Kilford L, Lees AJ. Accuracy of clinical diagnosis of idiopathic Parkinson's disease. A clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry 1992; 55: 181-4.
29. Hunot S, Hirsch EC. Neuroinflammatory processes in Parkinson's disease. Ann Neurol 2003; 53: S49-58.
30. Ichise M, Toyama H, Innis RB, Carson RE. Strategies to improve neuroreceptor parameter estimation by linear regression analysis. J Cereb Blood Flow Metab 2002; 22: 1271-81.
31. Innis RB1, Cunningham VJ, Delforge J, Fujita M, Gjedde A, Gunn RN, et al. Consensus nomenclature for in vivo imaging of reversibly binding radioligands. J Cereb Blood Flow Metab 2007; 27: 1533-9.
32. Jucaite A, Cselényi Z, Arvidsson A, Ahlberg G, Julin P, Varnäs K, et al. Kinetic analysis and test-retest variability of the radioligand [11C](R)-PK11195 binding to TSPO in the human brain-a PET study in control subjects. EJNMMI Res 2012; 23: 2-15.
33. Kreisl WC, Fujita M, Fujimura Y, Kimura N, Jenko KJ, Kannan P, et al. Comparison of [11C]-(R)-PK 11195 and [11C]PBR28, two radioligands for translocator protein (18 kDa) in human and monkey: Implications for positron emission tomographic imaging of this inflammation biomarker. Neuroimage 2010; 49: 2924-32.
34. Kreisl WC, Jenko KJ, Hines CS, Lyoo CH, Corona W, Morse CL, et al, Biomarkers Consortium PET Radioligand Project Team. A genetic polymorphism for translocator protein 18 kDa affects both in vitro and in vivo radioligand binding in human brain to this putative biomarker of neuroinflammation. J Cereb Blood Flow Metab 2013; 33: 53-8.
35. Lindqvist D, Hall S, Surova Y, Nielsen HM, Janelidze S, Brundin L, et al. Cerebrospinal fluid inflammatory markers in Parkinson's disease-associations with depression, fatigue, and cognitive impairment. Brain Behav Immun 2013; 33: 183-9.
36. Logan J, Fowler JS, Volkow ND, Wolf AP, Dewey SL, Schlyer DJ, et al. Graphical analysis of reversible radioligand binding from timeactivity measurements applied to [N-11C-methyl]-(2)-cocaine PET studies in human subjects. J Cereb Blood Flow Metab 1990; 10: 740-7.
37. McGeer PL, McGeer EG. Glial reactions in Parkinson's disease. Mov Disord 2008; 23: 474-83.
38. Müller T, Blum-Degen D, Przuntek H, Kuhn W. Interleukin-6 levels in cerebrospinal fluid inversely correlate to severity of Parkinson's disease. Acta Neurol Scand 1998; 98: 142-4.
39. Ondo WG. Motor complications in Parkinson's disease. Int J Neurosci 2011; 121 (Suppl 2): 37-44.
40. Ouchi Y, Yoshikawa E, Sekine Y, Futatsubashi M, Kanno T, Ogusu T. Microglial activation and dopamine terminal loss in early Parkinson's disease. Ann Neurol 2005; 57: 168-75.
41. Owen DR, Guo Q, Kalk NJ, Colasanti A, Kalogiannopoulou D, Dimber R, et al. Determination of [(11)C]PBR28 binding potential in vivo: A first human TSPO blocking study. J Cereb Blood Flow Metab 2014; 34: 989-94.
42. Owen DR, Howell OW, Tang SP, Wells LA, Bennacef I, Bergstrom M, et al. Two binding sites for [3H]PBR28 in human brain: implications for TSPO PET imaging of neuroinflammation. J Cereb Blood Flow Metab 2010; 30: 1608-18.
43. Owen DR, Yeo AJ, Gunn RN, Song K, Wadsworth G, Lewis A, et al. An 18-kDa Translocator Protein (TSPO) polymorphism explains differences in binding affinity of the PET radioligand PBR28. J Cereb Blood Flow Metab 2011; 32: 1-5.
44. Sasaki T, Ito H, Kimura Y, Arakawa R, Takano H, Seki C, et al. Quantification of dopamine transporter in human brain using PET with 18F-FE-PE2I. J Nucl Med 2012; 53: 1065-73.
45. Schain M, Varnäs K, Cselényi Z, Halldin C, Farde L, Varrone A. Evaluation of two automated methods for PET region of interest analysis. Neuroinformatics 2014; 12: 551-62.
46. Stefanova N, Reindl M, Neumann M, Haass C, Poewe W, Kahle PJ, et al. Oxidative stress in transgenic mice with oligodendroglial alpha-synuclein overexpression replicates the characteristic neuropathology of multiple system atrophy. Am J Pathol 2005; 166: 869-76.
47. Stepanov V, Krasikova R, Raus L, Loog O, Hiltunen J, Halldin C. An efficient one-step radiosynthesis of [18F] FE-PE2I, a PET radioligand for imaging of dopamine transporters. J Label Com Parkinson's disease. Radiopharm 2012; 55: 206-10.
48. Tzourio-Mazoyer N, Landeau B, Papathanassiou D, Crivello F, Etard O, Delcroix N, et al. Automated anatomical labeling of activiations in SPM using a macroscopic anatomical parcellation of the MNI MRI single subject brain. NeuroImage 2002; 15: 273-89.
49. Varrone A, Sjöholm N, Eriksson L, Gulyas B, Halldin C, Farde L. Advancement in PET quantification using 3D-OP-OSEM point spread function reconstruction with the HRRT. Eur J Nucl Med Mol Imaging 2009; 36: 1639-50.